According to the Astellas, Mirabegron is a once daily oral ß3-adrenoceptor agonist discovered and developed by the company. Mirabegron enhances the urine collection function by activating ß3-adrenoceptor on
The researchers at Kyoto University are led by professor Shinya Yamanaka, director of Kyoto University’s Center for iPS Cell Research and Application (CiRA). They are using the SmartChip
Data from the phase III Tender study showed that, following three months’ treatment with RoActemra, 85% of patients achieved 30% improvement (JIA ACR30) in the signs and symptoms
Under the partnership, Proteo will offer USAMRIID with Elafin and related scientific data to plan and conduct preclinical research on the development of new therapeutic strategies to combat
The new applications of RNAi technology define opportunities for the advancement of novel vaccines in many human diseases, including infectious disease and cancer. Alnylam is collaborating with the
Vitrolife is acquiring 25% of the shares of HertART, with an option to acquire up to 100%. The purchase sum amounts to DKK 2m. For the Vitrolife Group
Highmark will administer health insurance coverage to about 140,000 new members on behalf of PEBTF. Deborah Rice, executive vice president for health services at Highmark, said: “I believe
The study was conducted at The Ohio State University Comprehensive Cancer Center, Arthur James Cancer Hospital and Richard Solove Research Institute (OSUCCC-James). Arno said that the primary objective
Zenpep is an FDA-approved pancreatic enzyme product (PEP) used for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions. Zenpep has
FDA warned the consumers who had already faced adverse reactions from penicillin products and said that they are at risk of experiencing similar reactions from cloxacillin. This includes
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.